Despite medical advances, Pneumocystis jirovecii remains a major cause of lethal pneumonia (Pneumocystis pneumonia [PCP] ) in patients with HIV infection. A recent study of Ͼ500 episodes of PCP in patients with HIV infection at a single medical center revealed no statistically significant changes in the mortality rate over the past 2 decades [1] . The development of sensitive molecular techniques has permitted detection of P. jirovecii in the respiratory tract of different patient populations. The highest frequency of P. jirovecii colonization or subclinical infection occurs among patients with HIV infection; specific risk factors, such as low CD4 ϩ cell counts and smoking, have been identified [2] . P. jirovecii colonization induces local and systemic inflammatory responses and has been associated with moresevere airway obstruction [3, 4] . Thus, the potential problems resulting from the interaction of P. jirovecii with its human host extend not only to immunocompromised patients but also to immunocompetent patients.
Analysis of immune responses to P. jirovecii has long been hampered by the lack of suitable reagents [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The development of recombinant P. jirovecii antigens has begun to change this situation [15] [16] [17] [18] [19] [20] . We selected the major surface glycoprotein (Msg) as our target antigen, because it is highly immunogenic, contains protective B and T cell epitopes, and plays a central role in the interaction of the organism with the host [21] [22] [23] [24] [25] . We developed 3 overlapping recombinant fragments (MsgA, MsgB, and MsgC) that span the entire length of a single Msg isoform. Our studies have shown that MsgC, the carboxyl terminus, is the fragment that is most strongly recognized by serum antibodies of patients with HIV infection who have recovered from PCP [19, 20, 26] . To better delineate this antibody reactivity, we developed 3 variants of our original MsgC (termed MsgC1)-MsgC3, MsgC8, and MsgC9 -which exhibited 70%-99% homology at the amino acid level [27] . So far, our studies have shown that these variants react with serum specimens independently, but they also seem to have unique epitopes.
The Multicenter AIDS Cohort Study (MACS) is an ongoing, prospective cohort study of HIV infection in men who have sex with men that began in 1984 and involves 4 cities: Baltimore, Maryland; Chicago, Illinois; Pittsburgh, Pennsylvania; and Los Angeles, California. The careful patient follow-up and extensive database of the MACS have made it an invaluable resource for numerous studies of HIV infection and its complications. From 1992 through 2000, 106 patients from this cohort died and had lung tissue samples obtained at autopsy. Fifteen patients died from PCP. Ninety-one patients died from other causes, and of these, 42 (46%) were colonized with P. jirovecii, as determined by polymerase chain reaction (PCR) [28] . Multivariate analysis showed that cigarette smoking was associated with an increased risk for colonization, whereas residence in Los Angeles was associated with a decreased risk. These data raised intriguing questions about the relationship between the clinical and epidemiologic factors of P. jirovecii colonization, the occurrence of PCP, and serologic responses to Msg.
In the present study, we have examined the serologic responses to the MsgC constructs over the last 5.5 years of life in these MACS patients according to their status at death (PCP, P. jirovecii colonization, or neither), the specific host and environmental factors for all patients associated with high antibody levels, and whether the first AIDS-defining illness was PCP.
PATIENTS, MATERIALS, AND METHODS

Study population.
Of the 106 MACS patients who had undergone autopsy from 1992 through 2000, 100 had antemortem serum specimens available for analysis. These 100 patients were determined either to have died from PCP on the basis of autopsy results (15 patients), to have been colonized with P. jirovecii on the basis of nested PCR of lung tissue specimens (37 patients), or to have had PCR results that were negative for both PCP and colonization (48 patients) [28] .
Data collection. MACS patients attended semiannual study visits involving medical history, physical examination, and collection of blood specimens. Clinical and laboratory data were entered into a central database, and blood specimens were stored at Ϫ70°C in a national repository. Patient demographic characteristics included age, race and/or ethnicity, season, smoking history (ever or never), and study site. Clinical data included previous episodes of PCP, history of other opportunistic infections or AIDS-defining illness and their dates of occurrence, use of PCP prophylaxis, and receipt of antiretroviral treatment, as defined by the use of use of Ͼ1 antiretroviral drug. Laboratory data included CD4 ϩ cell counts and HIV RNA levels. Study design and data analysis. To study at least 5 years of sequential antibody levels prior to the patient's death, we obtained serum samples for 5.5 years prior to death, because many patients did not have a serum sample obtained during the last 6 months of life. We divided the 5.5 years into 3 intervals: Ͻ2 years, 2-3 years, and 4 -5.5 years prior to death. These intervals approximated tertiles in the number of antibody observations and enabled us to clearly delineate the changes in antibody levels over time. This study was approved by the Institutional Review Boards of the University of Cincinnati (Cincinnati, Ohio) and the University of Pittsburgh (Pittsburgh, Pennsylvania).
Recombinant antigens. The DNA fragments containing genes encoding recombinant MsgC fragments were prepared via PCR with use of DNA isolated from P. jirovecii-infected lung tissue specimens or cloned msg genes as templates and Amplitaq enzyme (Applied Biosystems) to generate msg gene segments [19, 20, 26, 27] . The PCR products were cloned into the pET30 vector (Novagen), and the recombinant MsgC proteins were expressed in Escherichia coli and purified as described elsewhere [27] . Of the MsgC fragments, MsgC3 and MsgC9 were the most closely related (with 99% homology).
ELISA. The ELISA was performed as described elsewhere [20, 26, 27] , with some modifications. Serum specimens to be analyzed and the standard reference serum were tested against recombinant MsgC fragments; PBS without antigen was used as a negative control. The reactivity of each serum specimen to Msg was corrected by subtraction of the reactivity of that serum to PBS (mean optical density with Msg minus the mean optical density with PBS), and the results were quantified using the method of Bishop and Kovacs [17] . A standard serum with specificity for each construct in turn was generated by mixing a pool of 4 -6 serum samples with high reactivity to that construct. A standard curve was generated for each construct on each day of the assay and was used to calculate the units of reactivity to the Msg constructs. Each standard serum pool was assigned a value of 100 U of reactivity to its target Msg construct in 100 L of a 1:100 dilution of serum. Test serum samples were assayed at 1:100 to 1:200 dilutions to fit the linear portion of the standard curves, and units of reactivity were calculated taking the dilution into account. Samples whose values were below the standard curve were assigned the lowest possible value of 1 U.
Statistical analysis. Levels of antibody to MsgC antigens were known to be left censored at 1 U; therefore, tobit analyses were performed for calculating summary statistics and regression analyses of antibody data [29] . Logarithmic transformation was applied before analysis, which normalized the distribution of uncensored antibody data to satisfy the assumption of normality for hypothesis testing. Descriptive statistics were obtained to compare the demographic and clinical characteristics of 100 patients divided into 3 groups determined by cause of death (PCP or other) and P. jirovecii colonization at death (yes or no), if death resulted from a cause other than PCP. For continuous variables, differences among group means were evaluated by analysis of variance; for categorical variables, 2 tests were performed to test equality of percentages among groups. Differences in serum levels of antibody to MsgC fragments, CD4 ϩ cell counts, and viral load were analyzed by analysis of variance, with comparison of the geometric means of the 3 cause-of-death groups by time to death (Ͻ2 years, 2-3 years, and 4 -5.5 years). Multiple observations per patient were analyzed if they were within the same time interval. Differences among interval means were evaluated by calculating 95% confidence intervals (CI)s.
Because of small sample sizes and the similarity of means (primarily between the 2 groups of patients who did not die from PCP), the analyses were repeated for 2 groups: those with death due to PCP versus those with death due to other causes. Mean values and 95% CIs of MsgC fragments among the 4 patient sites by time to death were compared between the 2 patient groups. Multiple regression analyses of levels of antibodies to each MsgC fragment were performed to investigate the effect of PCP diagnosis, compared with diagnosis of another AIDS-defining illness, on subsequent antibody levels in 92 patients with at least 1 AIDS-defining illness. These analyses were performed while controlling for the following covariates: prior PCP diagnosis (yes vs. no), patient race, location (city) of study site, age group (Ͻ36 years, 36 -46 years, or Ͼ46 years), antiretroviral treatment at time of observation (yes vs. no), receipt of prophylaxis at the time of observation (yes vs. no), smoking status (ever vs. never), and continuously measured CD4 ϩ cell count at the time of observation. Multiple observations of levels of antibodies to each antigen for the same patient were assumed to be independent because of the imbalance in number of observations per patient and changes in antibody levels. Antibody measurements for the same patient may have been analyzed first in the non-PCP category and later in the PCP category, but not vice versa. Analyses were performed using SAS for Windows (version 9.1; SAS Institute). The level of statistical significance was .05, unless stated otherwise.
RESULTS
Patients grouped by death status.
Persons who died from PCP did not differ significantly from patients who were colonized or not colonized with P. jirovecii in terms of age at death or age at first AIDS-defining illness, number of observations, years of follow-up or years between last clinic visit and death, smoking history, or use of PCP prophylaxis (table 1) . Statistically significant differences were found in the prevalence of previous episodes of PCP among patients who died from PCP (9 of 15; 60%), compared with that among colonized or noncolonized patients (9 of 37; 26%; P Ͻ .05). Of the white/non-Hispanic patients, 10% (8 of 77) died from PCP, and 42% (32 of 77) were colonized with P. jirovecii, whereas among the nonwhite patients, 30% (7 of 23) died from PCP, and only 22% (5 of 23) were colonized (P Ͻ .05). Of the 4 different geographic locations, Pittsburgh had the highest percentage of patients who died from PCP (4 of 17; 24%; P Ͻ .05); by contrast, Chicago had the highest percentage of patients who were colonized with the organism (15 of 26; 58%; P Ͻ .05). Differences were also found in the prevalence of antiretroviral treatment received in the 2 years before death by patients who died from PCP (6 of 13; 46%), compared with that received by colonized (27 of 32; 84%) and noncolonized patients (26 of 36; 72%; P Ͻ .05).
Because there were no statistically significant differences in the levels of antibody to the MsgC fragments or in CD4 ϩ cell counts between the colonized and noncolonized patients, these groups were combined for data analysis in this part of the study ( figure 1 ). There was a progressive decrease in CD4 ϩ cell counts and increase in HIV load over time, such that within the last 2 years before death, the patients who died from PCP had statistically significantly lower CD4 ϩ cell counts (mean, 38 vs. 76 cells/ L; P Ͻ .05) and higher viral loads (mean, 176,000 vs. 52,000 copies/mL; P Ͻ .05) than did patients who died of other causes.
Antibody levels in the colonized and noncolonized patients were similar throughout the 5.5 years of the study; thus, these groups were combined in the analysis (table 2) . Serum levels of antibody to MsgC8 were statistically significantly higher in patients who died from PCP than they were in patients who died from other causes, both at 2-3 years before death (P Ͻ .05) and according to an analysis of all of the data points (P Ͻ .05). Antibody levels to MsgC1 and MsgC3 tended to be higher among patients with PCP at Ͻ2 years, 2-3 years, and overall. In contrast, levels of antibody to MsgC9 tended to be higher among patients who died of causes other than PCP.
Seasonal and geographic effects on serum antibody levels. Analysis of the effects of environmental factors revealed no seasonal differences in levels of antibody to any of the MsgC fragments (data not shown). However, clear differences were found in the distribution of levels of antibody to the fragments between the study sites. These differences were evident in reactivity to MsgC1 at 4 -5.5 years and at 2-3 years before death, with Chi-cago having the highest antibody levels and Baltimore having the lowest (P Ͻ .01) (figure 2). Reactivity to MsgC3 also showed highest antibody levels in Chicago patients at 4 -5.5 years (P Ͻ .01), but antibody levels in Baltimore patients increased over time. Statistically significant differences (P Ͻ .01) were found in the reactivity to MsgC8 at 4 -5.5 years and 2-3 years; the highest levels of antibody to MsgC8 were found in patients from Chicago and Los Angeles, whereas lower antibody levels were found in patients from Baltimore. The highest levels of antibody to MsgC9 were found in Chicago patients in all phases of the study, but these results never reached statistical significance.
Factors associated with high serum antibody levels. Prior PCP was significantly associated with high levels of antibody to MsgC1, MsgC3, and MsgC9, and a trend was found for MsgC8 (table 3) . Higher antibody levels were associated with previous PCP than with any other variable. Age and study site were also independently associated with higher levels of antibody to all 4 MsgC fragments. Of the age groups, persons 36 -46 years of age had the highest antibody levels. Of the cities, study participants in Chicago and Pittsburgh consistently had the highest antibody levels, whereas patients in Baltimore and Los Angeles had the lowest levels. Failure to use PCP prophylaxis was independently associated with higher levels of antibody to MsgC1, but this association did not reach statistical significance with the other MsgC fragments. Additional factors, including race, CD4 ϩ cell count, smoking status, and receipt of antiretroviral therapy, were examined but were not found to be independently related to high antibody levels.
Serum antibody responses after recovery from PCP. Of 92 patients who developed their first AIDS-defining illness during the study, 17 had PCP (case patients), and 75 had another disorder (control subjects). Ten (59%) of the case patients and 31 (41%) of the control subjects had serum specimens obtained before and after the episodes (table 4). Because patients in the protocol were seen every 6 months, these specimens were obtained at least 6 months apart. The case patients demonstrated a 2.0 -2.8-fold increase in mean levels of antibody to all 4 MsgC fragments, whereas no increase occurred in the control subjects. The differences in mean postepisode levels of antibody to MsgC3 and MsgC8 between case patients and control subjects were statistically significant (P Ͻ .05).
We also compared the proportion of case patients who developed an increase in serum antibody levels with the proportion of control subjects who developed an increase. In a previous study, we found that 56% of individuals with HIV infection who had PCP developed an increase in levels of serum antibodies to Msg at 3-4 weeks, ranging from 1.4-fold to 22-fold above baseline (i.e., between the convalescent and acute specimens) [26] . An earlier report that used native Msg as the antigen defined a positive antibody response in individuals with HIV infection as a 2-fold increase above baseline [11] . On the basis of these studies and an examination of our data, we defined a 1.5-fold increase in antibody levels above baseline as a positive response. Four (40%) of the case patients had a statistically significant antibody response to MsgC1, MsgC8, and MsgC9, compared with 3 (10%) of the control subjects, for an odds ratio (95% CI) of 6.2
Figure 1. Geometric mean (95% confidence interval) values for CD4
ϩ cell count and HIV load for 100 individuals with HIV infection who died from Pneumocystis pneumonia (PCP) and other causes at different stages during the 5.5 years before death. *P Ͻ .05. NOTE. Boldface type indicates P Ͻ .05. Serum antibody levels were calculated from a standard curve in which the standard serum pool was assigned a value of 100 U; specimens below the curve were assigned the lowest possible value of 1 U. CI, confidence interval; Msg, major surface glycoprotein; PCP, Pneumocystis pneumonia. 
DISCUSSION
The present study has examined the sequential serum antibody responses to recombinant MsgC fragments in 100 MACS patients over the last 5.5 years of their lives. When grouped by status at death, patients who died from PCP had significantly higher mean levels of antibody to MsgC8 than did patients who died from other causes. Patients who died from PCP had moreadvanced HIV disease, were more immunosuppressed, and had a higher frequency of prior PCP than did patients who died from other causes. The patients with PCP tended to be nonwhite and to live in Pittsburgh, whereas the colonized patients tended to be white/non-Hispanic and to reside in Chicago. The reasons for the racial and geographic differences in PCP and P. jirovecii colonization are unclear, but socioeconomic factors, such as access to care, may also play a role.
When data for the entire cohort were analyzed, prior PCP was an independent predictor of high levels of antibody to the MsgC fragments, thus confirming and extending the findings of our previous cross-sectional studies [20, 27] . In those studies, higher levels of antibody to multiple MsgC fragments and more- Figure 2 . Geometric mean (95% confidence interval) levels of antibody to MsgC1, MsgC3, MsgC8, and MsgC9 for 100 patients, by geographic location and time before death. Serum antibody levels were calculated from a standard curve in which the standard serum pool was assigned a value of 100 U; specimens below the curve were assigned the lowest possible value of 1 U. Bal, Baltimore, Maryland; Chi, Chicago, Illinois; L.A., Los Angeles, California; Pit, Pittsburgh, Pennsylvania. frequent recognition of these fragments by Western blot testing distinguished individuals with HIV infection who had recovered from previous PCP from patients who had never had PCP [27] . In the present report, previous PCP appeared to be the strongest predictor of high antibody levels.
A second independent predictor of high antibody levels was geographic location. The MsgC fragments were derived from a patient with PCP who died in Cincinnati. Patients who resided in cities that were closer to Cincinnati (e.g., Chicago and Pittsburgh) generally had higher levels of antibody to the fragments Table 3 . Predicted mean antibody levels for 92 patients with HIV infection who had received a diagnosis of Pneumocystis pneumonia (PCP) or another AIDS-defining illness within 5.5 years before death, by antigen. NOTE. Results were obtained from repeated-measures regression analyses that included PCP status prior to antibody measurement (yes vs. no), age at the time of antibody measurement (Ͻ36 years, 36 -46 years, Ͼ46 years), race (white/non-Hispanic vs. other), location (city) of patient care, CD4 ϩ cell count at time of antibody measurement, history of smoking (ever vs. never), receipt of PCP prophylaxis at visit (yes vs. no), and receipt antiretroviral therapy at visit (yes vs. no). Serum antibody levels were calculated from a standard curve in which the standard serum pool was assigned a value of 100 U; specimens below the curve were assigned the lowest possible value of 1 U. Msg, major surface glycoprotein. NOTE. Serum antibody levels were calculated from a standard curve in which the standard serum pool was assigned a value of 100 U; specimens below the curve were assigned the lowest possible value of 1 U. CI, confidence interval; Msg, major surface glycoprotein.
a P Ͻ .05 for the mean differences between case patients and control subjects at each time period.
than did patients who lived in cities that were further away. It is possible that these differences represented strain or antigenic differences in P. jirovecii isolates. Msg is encoded by a multigene family and is thus capable of antigenic variation [25] . We have found different patterns of antibody reactivity in Spain and Cameroon (P.D.W. and K.R.D., unpublished data). Even though seasonal differences in antibody levels were not found, climatic factors, such as temperature and humidity, have been shown to influence the occurrence of PCP [29 -32] and might have had an effect here. Age was another independent predictor of high levels of antibody to the MsgC fragments. The highest antibody levels occurred in individuals 36 -46 years of age, which corresponded with the ages at which most cases of PCP occurred. Lack of PCP prophylaxis was associated with high antibody levels, but statistical significance was reached only with respect to MsgC1. These data suggest that PCP prophylaxis not only reduces the incidence of PCP but also appears to reduce the level or duration of exposure to the organism, which is associated with lower antibody response.
Individuals with HIV infection who experienced PCP during the study were more likely to develop a significant increase in levels of antibody to the MsgC fragments than were patients who experienced another disorder as their first AIDS-defining illness. This result suggests that the increase in antibody levels is specific for P. jirovecii. We have previously shown that a first episode of PCP and a CD4 ϩ cell count of Ͼ50 cells/L were the principal host factors associated with an increase in serum antibody levels immediately after recovery from PCP [26] . In both of these studies, the antibodies detected were of the IgG class; additional studies to determine the IgG subclass of these antibodies and whether IgM antibodies can be detected would be of interest. Because of the small number of patients with active PCP in our study, we were not able to adequately examine the role of CD4 ϩ cells in these antibody responses.
The results in the present report are also of interest because the pre-and postepisode serum specimens were obtained at least 6 months before and 6 months after the episode of PCP, respectively. These data also support the idea that some patients who recover from PCP have persistently high serum levels of antibody to the MsgC fragments. Additional investigation of these antibody responses and the host factors associated with them is warranted.
There are several limitations to this study. The small number of patients (especially those who died from PCP) emphasizes the need for caution in extrapolating the results reported here to other study situations. The patient population (men who have sex with men) and study period (mainly before the advent of highly active antiretroviral therapy [HAART]) also limited the applicability of the results. The lack of serum specimens obtained close to the time of autopsy made it difficult to correlate antibody levels, CD4 ϩ cell counts, and other laboratory values with the presence of P. jirovecii infection or colonization at death.
The present study has used the analysis of sequential serum antibody responses to recombinant Msg antigen fragments in a well-defined cohort population to produce new information about the epidemiologic features and host immunologic responses to P. jirovecii infection in individuals with HIV infec- tion. Some of the associations (e.g., geographic location and high antibody levels) that were found applied to all MsgC fragments, whereas other findings (death from PCP and antibody levels) applied to a specific MsgC fragment (MsgC8). The reasons for these differences are unclear, but they probably reflect differences in the question being asked or the analysis being performed. It is also unknown whether these antibody responses are associated with protective immunity. Further studies comparing the location and nature (shared or unique) of the MsgC epitopes recognized by antibodies associated with recovery from PCP with the MsgC epitopes recognized by antibodies associated with other factors (e.g., geographic location and age) will help to address this issue. In addition, PCP prophylaxis can be safely discontinued for patients with HIV infection who achieve durable suppression of plasma HIV RNA and immune reconstitution. Thus, longitudinal comparisons of antibody levels before and after HAART-driven immune reconstitution may be useful in understanding whether these specific antibody responses contribute to protection against PCP in the context of successful HAART. On a broader level, serological testing can also be applied to conditions ranging from P. jirovecii colonization to the association of host receptor polymorphisms and susceptibility to PCP in individuals with HIV infection [2, [33] [34] [35] [36] .
